Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 0.63 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586657 | 1.00 | HCAR2 (0.63) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599559 | 1.00 | HCAR2 (0.63) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5610946 | 0.81 | HCAR2 (0.54) | HCAR2DAOHCAR3KDM4ENPC1 | |
| SCHEMBL5610945 | 0.81 | HCAR2 (0.54) | HCAR2DAOHCAR3KDM4ENPC1 | |
| SCHEMBL14586656 | 0.81 | HCAR2 (0.63) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599204 | 0.81 | HCAR2 (0.63) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599209 | 0.81 | HCAR2 (0.63) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL21810960 | 0.78 | HCAR2 (1.00) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL31291499 | 0.78 | HCAR2 (0.54) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599431 | 0.77 | HCAR2 (0.58) | HCAR2DAOHCAR3CYTH3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122006606-A | Preparation method of aluminum-based MOF nanofiber aerogel | 东华大学 | 2026-05-12 | — | — | CN | claimed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | claimed |
| CN-122006606-A | Preparation method of aluminum-based MOF nanofiber aerogel | 东华大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4522155-A1 | NOVEL EXTENSION-FUNCTIONALIZATION STRATEGY FOR WATER-HARVESTING MOFS | The Regents of the University of California (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066392-A1 | Extension-Functionalization Strategy for Water-Harvesting MOFs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-27 | — | — | US | disclosed |
| CN-119212697-A | Novel extension functionalization strategy for water-collecting MOF | 加利福尼亚大学董事会 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023220514-A1 | NOVEL EXTENSION-FUNCTIONALIZATION STRATEGY FOR WATER-HARVESTING MOFS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1633351-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005011677-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066392-A1 | Extension-Functionalization Strategy for Water-Harvesting MOFs | EPCAM, CD44, AQP1 | HCAR2 3384/4885DAO 1660/4885HCAR3 2627/4885 |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | HCAR2 52/4885DAO 2261/4885HCAR3 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.